Read about alternatives to QALYs to assess whether the value of expected health benefits warrants the proposed additional costs, based on experiences from top minds in health technology assessment, in this publication: https://t.co/FSY0PVruUg https://t.co/
Interesting
@statnews Not unreasonable to consider the limitations of the QALY. But at least discuss the reasonable alternatives and why they have drawbacks as well. For instance, the new @PharmaEconomics article (https://t.co/HBv2la6MR5)
RT @PECjournal: Determining value in HTA - still considerable room for improvement https://t.co/i1o3l4OuWf @ProfJohnBrazier @jonkarnon et a…
RT @PECjournal: Determining value in HTA - still considerable room for improvement https://t.co/i1o3l4OuWf @ProfJohnBrazier @jonkarnon et a…
Determining value in HTA - still considerable room for improvement https://t.co/i1o3l4OuWf @ProfJohnBrazier @jonkarnon et al.
#HealthEconJA Determining Value in Health Technology Assessment: Stay the Course or Tack Away? https://t.co/KzqSNOdkOa